Odds and Ends 

uBiome is jumping into therapeutics with a healthy $83 million in Series C financing

23andMe, IBM and now uBiome is the next tech company to jump into the lucrative multi-billion dollar drug discovery market. The company started out with a consumer gut health test to check whether your intestines carry the right kind of bacteria for healthy digestion but has since expanded to include over 250,000 samples for everything from the microbes on your skin to vaginal health — the largest data set in the world for these types of samples, according to the company. Founder Jessica Richman now says there’s a wider opportunity…

Read More
Headlines 

23andMe’s Pharma Deals Have Been the Plan All Along

Since the launch of its DNA testing service in 2007, genomics giant 23andMe has convinced more than 5 million people to fill a plastic tube with half a teaspoon of saliva. In return for all that spit (and some cash too), customers get insights into their biological inheritance, from the superficial—do you have dry earwax or wet?—to mutations associated with disease. What 23andMe gets is an ever-expanding supply of valuable behavioral, health, and genetic information from the 80 percent of its customers who consent to having their data used for…

Read More
Headlines 

How private is your DNA? Police tap genealogy websites to find suspected ‘Golden State Killer.’

Do you know where your DNA data is?Image: Getty Images/Science Photo Library RM Think twice before you send companies your spit.  A suspected serial killer was caught when investigators compared his DNA to samples collected by ancestry websites. SEE ALSO: Facebook’s richer than ever, despite data privacy scandals Services like 23andMe and Ancestry have become popular by using DNA from users who want to learn more about their family history. But few people think the DNA samples they send in might be used by law enforcement.  On Tuesday, Joseph James…

Read More
Odds and Ends 

23andMe gets FDA green light for cancer risk test

Genetic testing powerhouse 23andMe announced today that it’s officially received the FDA go-ahead to launch a direct-to-consumer testing kit for genes linked to various forms of cancer. The forthcoming kit, which will be made available without a prescription, tests for BRCA1 and BRCA2, which are linked to higher risk of ovarian, break and prostate cancer. “Being the first and only direct-to-consumer genetics company to receive FDA authorization to test for cancer risk without a prescription is a major milestone for 23andMe and for the consumer,” the company’s CEO Anne Wojcicki…

Read More